v3.25.1
License and Collaboration Agreements - Additional Information (Detail)
1 Months Ended 3 Months Ended 12 Months Ended
Nov. 30, 2020
USD ($)
Jan. 31, 2024
USD ($)
Oct. 31, 2023
USD ($)
Apr. 30, 2023
USD ($)
Jan. 31, 2023
USD ($)
Jun. 30, 2022
USD ($)
Apr. 30, 2022
USD ($)
Aug. 31, 2021
USD ($)
Mar. 31, 2025
USD ($)
License
Mar. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Jan. 31, 2021
USD ($)
Oct. 31, 2020
USD ($)
SYFOVRE [Member]                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Royalty expense                 $ 4,200,000 $ 4,500,000      
Regulatory milestone payments   $ 3,000,000 $ 2,000,000 $ 2,300,000                  
Regulatory milestone incurred                     $ 5,000,000    
Empaveli And Aspaveli [Member]                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Royalty expense                 1,600,000 1,600,000      
Milestone payments based on annual sales milestones   1,500,000                      
Swedish Orphan Biovitrum AB (Publ) [Member] | Aspaveli [Member]                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Royalty revenue                 6,100,000 4,500,000      
Collaboration and License Agreement [Member] | Swedish Orphan Biovitrum AB (Publ) [Member]                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Revenue recognized                 10,800,000 4,800,000      
Upfront payment $ 250,000,000                        
Milestone payment received for achievement of regulatory development milestone             $ 50,000,000            
Development cost reimbursement received                 65,000,000        
Waived Payment                 $ 15,000,000        
Royalties entitled to receive after first commercial sale of applicable licensed product period                 10 years        
Contract research and development expense                 $ 0 $ 0      
Collaboration and License Agreement [Member] | Swedish Orphan Biovitrum AB (Publ) [Member] | Maximum [Member]                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Aggregate milestone payments upon achievement of specified one time regulatory development and commercial milestone events                         $ 915,000,000
Development cost reimbursement                 80,000,000        
University of Pennsylvania [Member]                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Development milestone achievement           $ 5,000,000   $ 1,000,000          
University of Pennsylvania [Member] | Empaveli And Aspaveli [Member]                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Milestone payments based on annual sales milestones         $ 1,000,000                
University of Pennsylvania [Member] | Maximum [Member]                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Aggregate milestones payments                 3,200,000        
Milestone payments based on annual sales milestones                 $ 5,000,000        
2010 License Agreement [Member]                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Number of licensed products | License                 2        
2010 License Agreement [Member] | Maximum [Member]                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Aggregate milestones payments                 $ 1,700,000        
Milestone payments based on annual sales milestones                 $ 2,500,000        
Sobi Agreement and Another Licensing Transaction [Member]                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Sublicense fee owed   $ 500,000                   $ 25,000,000